Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
Date:11/15/2007

CALGARY, Nov. 15 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the company at Toronto CFA Society on Tuesday, November 20, 2007. The event is being held at the National Club, 303 Bay Street, Toronto at 7:45 a.m.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

About Toronto CFA Society

Society membership is comprised of portfolio managers, investment analysts, corporate finance executives, academics, and other investment professionals who practice in a variety of fields, including investment counseling and management, banking, insurance, investment banking and brokerage firms, government agencies, regulators, and the financial media. Over 90% of members have a CFA designation.

The presentation times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
2. Mediatech Moves to Prince William County Innovation Park
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
6. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
7. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
10. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
11. BioLife Solutions Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... The Academy ... is now celebrating its dream of reaching a total of $1 million in awarded ... awarded to 10 high school graduates from across the nation has helped bring the ...
(Date:5/17/2016)... Texas (PRWEB) , ... May 17, 2016 , ... ... for use in animal waste reduction applications, announced today it will be showcasing ... Moines, Iowa. , ManureMagic™ was featured in the Wall Street Journal last year ...
(Date:5/17/2016)... (PRWEB) , ... May 17, 2016 , ... The Children’s ... bridges, and monuments across the globe will show their support in the fight against ... , Neurofibromatosis, NF, is a genetic disorder that causes tumors to grow on nerves ...
(Date:5/17/2016)... ... May 17, 2016 , ... Yukon Medical, a leading ... (Becton, Dickinson and Company) to receive its Global Product Innovation Supplier of the ... made significant contributions to advancing or supporting key BD initiatives, products, processes, and ...
Breaking Biology Technology:
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
(Date:3/15/2016)... Yissum Research Development Company of the ... the Hebrew University, announced today the formation of ... various human biological indicators. Neteera Technologies has completed its ... investors. ... electromagnetic emissions from sweat ducts, enables reliable and speedy ...
Breaking Biology News(10 mins):